Sale!

DYNC1H1 Gene Spinal Muscular Atrophy Lower Extremity-Predominant Type 1 Autosomal Dominant Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The DYNC1H1 gene plays a crucial role in the development and function of the nervous system, and mutations in this gene can lead to various neurological conditions, including Spinal Muscular Atrophy Lower Extremity-Predominant Type 1 (SMA-LED1), an autosomal dominant disorder. This particular form of spinal muscular atrophy is characterized by muscle weakness and atrophy primarily affecting the lower limbs. Unlike other forms of SMA, SMA-LED1 shows a pattern of inheritance where only one copy of the mutated gene from either parent is sufficient to cause the disorder.

To diagnose this condition, a genetic test is available at DNA Labs UAE, which specifically looks for mutations in the DYNC1H1 gene associated with SMA-LED1. The test is a crucial tool for confirming the diagnosis, understanding the risk of passing the condition to offspring, and guiding management and treatment decisions. The cost of the test is 4400 AED, reflecting the sophisticated technology and expertise required to accurately identify mutations in the DYNC1H1 gene. Conducting this test at DNA Labs UAE ensures access to state-of-the-art genetic testing services, provided by a team of professionals specialized in genetic disorders.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

DYNC1H1 Gene Spinal Muscular Atrophy Lower Extremity-Predominant Type 1 Autosomal Dominant Genetic Test

Are you or your loved ones experiencing symptoms of Spinal Muscular Atrophy, Lower Extremity-Predominant Type 1? DNA Labs UAE offers a comprehensive genetic test to diagnose this rare genetic disorder. Read on to learn more about the test and its components.

Test Name: DYNC1H1 Gene Spinal Muscular Atrophy Lower Extremity-Predominant Type 1 Autosomal Dominant Genetic Test

  • Components: DYNC1H1 gene analysis
  • Price: 4400.0 AED
  • Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
  • Report Delivery: 3 to 4 Weeks
  • Method: NGS Technology
  • Test Type: Neurological Disorders
  • Doctor: Neurologist
  • Test Department: Genetics

Pre Test Information

Before undergoing the DYNC1H1 gene test, it is essential to provide the clinical history of the patient. Additionally, a genetic counseling session will be conducted to draw a pedigree chart of family members affected by Spinal Muscular Atrophy, Lower Extremity-Predominant Type 1, autosomal dominant.

Test Details

The DYNC1H1 gene is associated with Spinal Muscular Atrophy, Lower Extremity-Predominant Type 1, a rare genetic disorder. This disorder is inherited in an autosomal dominant manner, meaning that affected individuals have a 50% chance of passing on the gene mutation to their children.

NGS (Next-Generation Sequencing) Genetic Testing is utilized to analyze multiple genes simultaneously and identify mutations or variations linked to specific conditions. In the case of DYNC1H1 gene testing, NGS technology is used to detect any mutations or variations in the gene that may cause Spinal Muscular Atrophy, Lower Extremity-Predominant Type 1.

The genetic test involves collecting a DNA sample, typically through a blood sample or cheek swab. The collected DNA is then analyzed using NGS technology to identify any mutations or variations in the DYNC1H1 gene.

The test results can help confirm a diagnosis of Spinal Muscular Atrophy, Lower Extremity-Predominant Type 1 and provide information about the inheritance pattern within a family.

It is crucial to note that genetic testing is a complex process and should be conducted under the guidance of a healthcare professional or genetic counselor. They can interpret the results and offer appropriate counseling and support for individuals and families affected by this genetic disorder.

Test Name DYNC1H1 Gene Spinal muscular atrophy lower extremity-predominant type 1 autosomal dominant Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card o
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Neurological Disorders
Doctor Neurologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for DYNC1H1 Gene Spinal muscular atrophy, lower extremity-predominant type 1, autosomal dominant NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with DYNC1H1 Gene Spinal muscular atrophy, lower extremity-predominant type 1, autosomal dominant
Test Details

The DYNC1H1 gene is associated with a rare genetic disorder called Spinal Muscular Atrophy, Lower Extremity-Predominant Type 1. This disorder is inherited in an autosomal dominant manner, meaning that an affected individual has a 50% chance of passing on the gene mutation to each of their children.

NGS (Next-Generation Sequencing) Genetic Testing is a method used to analyze multiple genes simultaneously to identify mutations or variations that may be associated with a specific condition. In the case of DYNC1H1 gene testing, NGS can be used to identify any mutations or variations in the gene that may be causing the Spinal Muscular Atrophy, Lower Extremity-Predominant Type 1 disorder.

This genetic test involves collecting a sample of DNA, typically through a blood sample or a cheek swab. The DNA is then analyzed using NGS technology to identify any mutations or variations in the DYNC1H1 gene. The results of the test can help confirm a diagnosis of Spinal Muscular Atrophy, Lower Extremity-Predominant Type 1 and provide information about the inheritance pattern within a family.

It is important to note that genetic testing is a complex process and should be done under the guidance of a healthcare professional or genetic counselor. They can help interpret the results and provide appropriate counseling and support for individuals and families affected by this genetic disorder.